ALNY vs CAI: fair value comparison
Alnylam Pharmaceuticals, Inc. and Caris Life Sciences, Inc. · Updated 2026-10-19
ALNY is still awaiting a full valuation verdict under our six-validated-windows standard. CAI's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, ALNY currently ranks higher by quality score.
| ALNY | CAI | |
|---|---|---|
| Verdict | Awaiting full valuation | Awaiting full valuation |
| Last price | $231.83 | $30.56 |
| 12-month range | $205.48–$481.59 | $14.55–$32.27 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #22 of 301 Healthcare | #24 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: ALNY fair value analysis · CAI fair value analysis